<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.biopharminternational.com/view/q-a-with-dr-mazen-noureddin-once-monthly-efimosfermin-and-fibrosis-improvement-in-mash</loc>
      <lastmod>2026-11-19T20:49:35.235Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:49:35.235Z</news:publication_date>
        <news:title><![CDATA[Q&A with Dr. Mazen Noureddin: Once-Monthly Efimosfermin and Fibrosis Improvement in MASH]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/application-note-validation-of-hamilton-tcd-sensor-during-pichia-pastoris-fermentation</loc>
      <lastmod>2026-11-19T20:32:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:32:00Z</news:publication_date>
        <news:title><![CDATA[Application Note - Validation of Hamilton TCD Sensor During Pichia pastoris Fermentation]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/application-note-in-line-turbidity-measurement-to-monitor-clarification-efficiency-in-cell-culture-harvests</loc>
      <lastmod>2026-11-19T20:32:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:32:00Z</news:publication_date>
        <news:title><![CDATA[Application Note - In-line Turbidity Measurement to Monitor Clarification Efficiency in Cell Culture Harvests]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-a-matrix-targeting-adc-in-head-and-neck-cancer-an-rnai-approval-in-myasthenia-gravis-and-abbvie-bets-on-and-gated-bispecifics</loc>
      <lastmod>2026-11-19T19:43:58.690Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:43:53.694Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/why-dmmr-rectal-tumors-respond-to-pd-1-blockade-alone-says-msk-s-andrea-cercek</loc>
      <lastmod>2026-11-19T19:43:09.311Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:43:09.311Z</news:publication_date>
        <news:title><![CDATA[Why dMMR Rectal Tumors Respond to PD-1 Blockade Alone, Says MSK's Andrea Cercek]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/pyxis-matrix-targeting-adc-micvo-shows-39-response-rate-and-9-2-month-median-response-duration-in-previously-treated-head-and-neck-cancer</loc>
      <lastmod>2026-11-19T15:56:45.413Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:56:40.465Z</news:publication_date>
        <news:title><![CDATA[Pyxis’ Matrix-Targeting ADC MICVO Shows 39% Response Rate and 9.2-Month Median Response Duration in Previously Treated Head and Neck Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-approves-cemdisiran-livsayis-first-rnai-therapy-myasthenia-gravis</loc>
      <lastmod>2026-11-19T14:48:35Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:48:35Z</news:publication_date>
        <news:title><![CDATA[FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/abbvie-and-disco-partner-on-and-gated-bispecifics-designed-to-recognize-tumor-selective-protein-pairs</loc>
      <lastmod>2026-11-19T14:37:08.614Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:37:08.614Z</news:publication_date>
        <news:title><![CDATA[AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/evotec-bristol-myers-squibb-second-ind-acceptance-celmod-molecular-glue-degrader</loc>
      <lastmod>2026-11-19T14:27:12Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:27:12Z</news:publication_date>
        <news:title><![CDATA[Evotec, BMS Gain Second FDA IND Acceptance for Molecular Glue Degrader]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-a-first-for-streamlined-biosimilar-approval-a-head-to-head-bispecific-trial-in-wet-amd-and-in-vivo-kir-car-t</loc>
      <lastmod>2026-11-17T21:52:14.074Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:30:52.987Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/salalah-free-zone-a-gateway-for-pharmaceutical-and-medtech-investment</loc>
      <lastmod>2026-11-18T19:51:14.916Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:51:14.916Z</news:publication_date>
        <news:title><![CDATA[Salalah Free Zone: A Gateway for Pharmaceutical and MedTech Investment ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/mabxience-oncoprecision-onc001-adc-manufacturing-investment-agreement</loc>
      <lastmod>2026-11-18T15:22:52.745Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:22:52.745Z</news:publication_date>
        <news:title><![CDATA[mAbxience Backs OncoPrecision ADC With Investment, Manufacturing Deal]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/verismo-licenses-stanford-pack-it-in-vivo-kir-car-t-platform</loc>
      <lastmod>2026-11-18T14:33:44Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:33:44Z</news:publication_date>
        <news:title><![CDATA[Verismo Licenses Stanford PACK-IT Tech for In Vivo KIR-CAR T Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/visara-doses-first-patient-in-phase-2b-trial-pitting-bispecific-vis-101-against-aflibercept-in-wet-amd</loc>
      <lastmod>2026-11-18T14:01:14.525Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:01:14.525Z</news:publication_date>
        <news:title><![CDATA[Visara Doses First Patient in Phase 2b Trial Pitting Bispecific VIS-101 Against Aflibercept in Wet AMD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/biocon-s-pebrilzo-becomes-first-breast-cancer-treatment-biosimilar-approved-under-ema-s-tailored-clinical-approach</loc>
      <lastmod>2026-11-18T13:19:22.946Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:19:22.946Z</news:publication_date>
        <news:title><![CDATA[Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach]]></news:title>
      </news:news>
	</url></urlset>